Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity.
Thalidomide is being increasingly used in the clinical management of a wide spectrum of immunologically-mediated and infectious diseases, and cancers. However, the mechanisms underlying its pharmacological action are still under investigation. In this regard, oral thalidomide is clinically valuable in the treatment of erythema nodosum leprosum (ENL) and multiple myeloma and effectively reduces tumor necrosis factor-alpha (TNF-alpha) levels and angiogenesis in vivo. This contrasts with its relatively weak effects on TNF-alpha and angiogenesis in in vitro studies and implies that active metabolites contribute to its in vivo pharmacologic action and that specific analogues would be endowed with potent activity. Our focus in the structural modification of thalidomide is toward the discovery of novel isosteric active analogues. In this regard, a series of thiothalidomides and analogues were synthesized and evaluated for their TNF-alpha inhibitory activity against lipopolysacharide (LPS)-stimulated peripheral blood mononuclear cells (PBMC), This was combined with a PBMC viability assay to differentiate reductions in TNF-alpha secretion from cellular toxicity. Two isosteric analogues of thalidomide, compounds 15 and 16, that mostly reflect the parent compound, together with the simple structure, dithioglutarimide 19, potently inhibited TNF-alpha secretion, compared to thalidomide, 1. The mechanism underpinning this most likely is posttranscriptional, as each of these compounds decreased TNF-alpha mRNA stability via its 3'-UTR. The potency of 19 warrants further study and suggests that replacement of the amide carbonyl with a thiocarbonyl may be beneficial for increased TNF-alpha inhibitory action. In addition, an intact phthalimido moiety appeared to be requisite for TNF-alpha inhibitory activity.
Zhu
Xiaoxiang
X
Drug Design & Development Section, Laboratory of Neurosciences, Gerontology Research Center (4E02), Intramural Research Program, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Dr., Baltimore, Maryland 21224-6825, USA.
Giordano
Tony
T
Yu
Qian-Sheng
QS
Holloway
Harold W
HW
Perry
Tracy Ann
TA
Lahiri
Debomoy K
DK
Brossi
Arnold
A
Greig
Nigel H
NH
D020413:3' Untranslated Regions; D000818:Animals; D002460:Cell Line; D017930:Genes, Reporter; D006801:Humans; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000494:pharmacology; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D051379:Mice; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D010880:Piperidines / Q000138:chemical synthesis* / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013329:Structure-Activity Relationship; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology; D013871:Thiones / Q000138:chemical synthesis* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
C479890:2,6-piperidinedithione; D020413:3' Untranslated Regions; D008070:Lipopolysaccharides; D010880:Piperidines; D012333:RNA, Messenger; D013871:Thiones; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D008156:Luciferases